Literature DB >> 15650202

Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy.

M C Strain1, S Letendre, S K Pillai, T Russell, C C Ignacio, H F Günthard, B Good, D M Smith, S M Wolinsky, M Furtado, J Marquie-Beck, J Durelle, I Grant, D D Richman, T Marcotte, J A McCutchan, R J Ellis, J K Wong.   

Abstract

Human immunodeficiency virus (HIV) infection of the central nervous system (CNS) is a significant cause of morbidity. The requirements for HIV adaptation to the CNS for neuropathogenesis and the value of CSF virus as a surrogate for virus activity in brain parenchyma are not well established. We studied 18 HIV-infected subjects, most with advanced immunodeficiency and some neurocognitive impairment but none with evidence of opportunistic infection or malignancy of the CNS. Clonal sequences of C2-V3 env and population sequences of pol from HIV RNA in cerebrospinal fluid (CSF) and plasma were correlated with clinical and virologic variables. Most (14 of 18) subjects had partitioning of C2-V3 sequences according to compartment, and 9 of 13 subjects with drug resistance exhibited discordant resistance patterns between the two compartments. Regression analyses identified three to seven positions in C2-V3 that discriminated CSF from plasma HIV. The presence of compartmental differences at one or more of the identified positions in C2-V3 was highly associated with the presence of discordant resistance (P = 0.007), reflecting the autonomous replication of HIV and the independent evolution of drug resistance in the CNS. Discordance of resistance was associated with severity of neurocognitive deficits (P = 0.07), while low nadir CD4 counts were linked both to the severity of neurocognitive deficits and to discordant resistance patterns (P = 0.05 and 0.09, respectively). These observations support the study of CSF HIV as an accessible surrogate for HIV virions in the brain, confirm the high frequency of discordant resistance in subjects with advanced disease in the absence of opportunistic infection or malignancy of the CNS, and begin to identify genetic patterns in HIV env associated with adaptation to the CNS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15650202      PMCID: PMC544082          DOI: 10.1128/JVI.79.3.1772-1788.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  101 in total

1.  Estimation of levels of gene flow from DNA sequence data.

Authors:  R R Hudson; M Slatkin; W P Maddison
Journal:  Genetics       Date:  1992-10       Impact factor: 4.562

2.  Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule.

Authors:  R A Fouchier; M Groenink; N A Kootstra; M Tersmette; H G Huisman; F Miedema; H Schuitemaker
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

3.  Demented and nondemented patients with AIDS differ in brain-derived human immunodeficiency virus type 1 envelope sequences.

Authors:  C Power; J C McArthur; R T Johnson; D E Griffin; J D Glass; S Perryman; B Chesebro
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

4.  In vivo comparison of zidovudine resistance mutations in blood and CSF of HIV-1-infected patients.

Authors:  B Wildemann; J Haas; K Ehrhart; H Wagner; N Lynen; B Storch-Hagenlocher
Journal:  Neurology       Date:  1993-12       Impact factor: 9.910

Review 5.  The neuropathogenesis of HIV-1 infection.

Authors:  H E Gendelman; S A Lipton; M Tardieu; M I Bukrinsky; H S Nottet
Journal:  J Leukoc Biol       Date:  1994-09       Impact factor: 4.962

6.  Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1.

Authors:  T Shioda; J A Levy; C Cheng-Mayer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

7.  V3 sequences of paired HIV-1 isolates from blood and cerebrospinal fluid cluster according to host and show variation related to the clinical stage of disease.

Authors:  B Keys; J Karis; B Fadeel; A Valentin; G Norkrans; L Hagberg; F Chiodi
Journal:  Virology       Date:  1993-10       Impact factor: 3.616

8.  Human immunodeficiency virus type 1 nef quasispecies in pathological tissue.

Authors:  B M Blumberg; L G Epstein; Y Saito; D Chen; L R Sharer; R Anand
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

9.  HIV-1 proviral genotypes from the peripheral blood mononuclear cells of an infected patient are differentially represented in expressed sequences.

Authors:  N L Michael; G Chang; P K Ehrenberg; M T Vahey; R R Redfield
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1993-10

10.  Virus escape from CTL recognition.

Authors:  R A Koup
Journal:  J Exp Med       Date:  1994-09-01       Impact factor: 14.307

View more
  77 in total

1.  Neurocognitive and motor deficits in HIV-infected Ugandan children with high CD4 cell counts.

Authors:  Theodore D Ruel; Michael J Boivin; Hannah E Boal; Paul Bangirana; Edwin Charlebois; Diane V Havlir; Philip J Rosenthal; Grant Dorsey; Jane Achan; Carolyne Akello; Moses R Kamya; Joseph K Wong
Journal:  Clin Infect Dis       Date:  2012-02-04       Impact factor: 9.079

Review 2.  Thinking about HIV: the intersection of virus, neuroinflammation and cognitive dysfunction.

Authors:  K Grovit-Ferbas; M E Harris-White
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

3.  Transmigration of macrophages across the choroid plexus epithelium in response to the feline immunodeficiency virus.

Authors:  Rick B Meeker; D C Bragg; Winona Poulton; Lola Hudson
Journal:  Cell Tissue Res       Date:  2012-01-27       Impact factor: 5.249

4.  Transcriptional activity of blood-and cerebrospinal fluid-derived nef/long-terminal repeat sequences isolated from a slow progressor infected with nef-deleted human immunodeficiency virus type 1 (HIV-1) who developed HIV-associated dementia.

Authors:  Melissa J Churchill; Anna Figueiredo; Daniel Cowley; Lachlan Gray; Damian Fj Purcell; John S Sullivan; Dale A McPhee; Steven L Wesselingh; Bruce J Brew; Paul R Gorry
Journal:  J Neurovirol       Date:  2006-06       Impact factor: 2.643

5.  Early virologic failure and the development of antiretroviral drug resistance mutations in HIV-infected Ugandan children.

Authors:  Theodore D Ruel; Moses R Kamya; Pelin Li; William Pasutti; Edwin D Charlebois; Teri Liegler; Grant Dorsey; Philip J Rosenthal; Diane V Havlir; Joseph K Wong; Jane Achan
Journal:  J Acquir Immune Defic Syndr       Date:  2011-01-01       Impact factor: 3.731

6.  Biomarkers of HIV-1-associated neurocognitive disorders: challenges of proteomic approaches.

Authors:  Pawel Ciborowski
Journal:  Biomark Med       Date:  2009-12       Impact factor: 2.851

7.  Discordant genotypic resistance and HIV-1 genetic diversity from paired plasma and cerebrospinal fluid samples in Chinese settings.

Authors:  Lifeng Liu; Yulin Zhang; Feili Wei; Qingxia Zhao; Xicheng Wang; Lin Yuan; Ning Li; Dexi Chen
Journal:  J Neurovirol       Date:  2013-01-17       Impact factor: 2.643

Review 8.  Compartmentalization, Viral Evolution, and Viral Latency of HIV in the CNS.

Authors:  Maria M Bednar; Christa Buckheit Sturdevant; Lauren A Tompkins; Kathryn Twigg Arrildt; Elena Dukhovlinova; Laura P Kincer; Ronald Swanstrom
Journal:  Curr HIV/AIDS Rep       Date:  2015-06       Impact factor: 5.071

9.  HIV-associated neurocognitive disorders and the impact of combination antiretroviral therapies.

Authors:  Beau M Ances; David B Clifford
Journal:  Curr Neurol Neurosci Rep       Date:  2008-11       Impact factor: 5.081

10.  Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection.

Authors:  Gretja Schnell; Richard W Price; Ronald Swanstrom; Serena Spudich
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.